PU.1/microRNA-142-3p targets ATG5/ATG16L1 to inactivate autophagy and sensitize hepatocellular carcinoma cells to sorafenib

Sorafenib is currently the only systemic agent approved for treatment of advanced hepatocellular carcinoma (HCC). However, intrinsic and acquired resistance to sorafenib remains a great challenge with respect to improving the prognoses of patients with HCC. The cyto-protective functions of autophagy...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Kai, Chen, Jing, Zhou, Hao, Chen, Ying, Zhi, Yingru, Zhang, Bei, Chen, Longbang, Chu, Xiaoyuan, Wang, Rui, Zhang, Chunni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5833744/
https://www.ncbi.nlm.nih.gov/pubmed/29472524
http://dx.doi.org/10.1038/s41419-018-0344-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5833744/
https://www.ncbi.nlm.nih.gov/pubmed/29472524
http://dx.doi.org/10.1038/s41419-018-0344-0

Ejemplares similares